Compare DYN & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DYN | WRBY |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2020 | 2021 |
| Metric | DYN | WRBY |
|---|---|---|
| Price | $18.21 | $29.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $37.00 | $27.10 |
| AVG Volume (30 Days) | 1.7M | ★ 2.5M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 105.88 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $871,905,000.00 |
| Revenue This Year | N/A | $14.48 |
| Revenue Next Year | N/A | $16.41 |
| P/E Ratio | ★ N/A | $984.00 |
| Revenue Growth | N/A | ★ 13.04 |
| 52 Week Low | $8.25 | $14.96 |
| 52 Week High | $25.00 | $31.00 |
| Indicator | DYN | WRBY |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 69.30 |
| Support Level | $16.47 | $21.22 |
| Resistance Level | $19.65 | $31.00 |
| Average True Range (ATR) | 0.98 | 1.76 |
| MACD | -0.10 | 0.75 |
| Stochastic Oscillator | 39.93 | 95.95 |
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.